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Summary.-Spleen-cell sensitivity to encephalitogenic factor (EF) was measured
with the macrophage migration inhibition (MMI) test over a period of time in
hamsters inoculated with SV40-transformed tumour cells and in rats treated with
4-dimethylamino-3'-methylazobenzene.
Spleen cells from hamsters receiving 10 or 103 SV40 tumour cells gave inhibition of
macrophage migration with EF at a significance level ofP<0*0521 days after implan-
tation. Spleen cells from animals receiving 105 tumour cells gave inhibition at a
significance level of P<0.001 after the same interval.
Spleen-cell sensitivity to EF, and the abrogation of this sensitivity by serum, was
investigated over a period of time in rats undergoing hepatocarcinogenesis. Sensitiv-
ity to EF was seen in 2/10 animals (20%) with minimal lesions of the liver, in 2/16
animals (12%) with proliferative changes and/or cholangiofibrosis, in 7/15 animals
(46%) with dysplastic lesions of portal-tract epithelial cells and in all 5 animals with
cholangiocarcinoma. None of a control group of 10 animals showed any response to
EF. Autologous serum abrogated the spleen-cell response to EF in one sensitized
animal with proliferative changes and cholangiofibrosis, in all 7 sensitized animals
with dysplastic hepatic lesions andin4/5 sensitized animals withcholangiocarcinoma.
Autologous serum had no effect on macrophage migration in the 10 control animals.
These findings indicate that a progressive increase in sensitization to EF occurs
during carcinogenesis and is evident at the point of preneoplastic dysplasia. This has
an obviously important bearing on the clinical use of such tests.
A DELAYED HYPERSENSITIVITY RES-
PONSE to encephalitogenic factor (EF) has
been demonstrated in malignant neo-
plastic disease with both the macrophage
migration inhibition (MMI) test (Light,
Preece and Waldron, 1975; Shelton,
Potter and Carr, 1975; Flavell and Potter,
1978) and the macrophage electrophoretic
mobility (MEM) test (Field and Caspary,
1970; Caspary and Field. 1971; Pritchard
et al., 1973; Goldstone, Kerr and Irvine,
1973). However, it is not clear at which
point in the neoplastic process such
sensitivity becomes apparent and this
remains one of the outstanding problems
related to the delayed hypersensitivity
response to this antigen in malignant
disease. Data from Field, Caspary and
Shepherd (1972) and Pritchard et al.
(1976) suggest that sensitivity manifests
itself many years before the appearance of
clinicallv detectable tumour. An early
lymphocyte response to EF during tumour
development was also reported by Singer
et al. (1975) and Porzsolt, Muhlberger and
Ax (1975), who detected sensitization to
EF in a large proportion of women with
cervical dysplasia.
Sensitivity to EF has also been reported
in a number of animal tumour systems.
Thus, Shelton et al. (1975) demonstrated a
delayed hypersensitivity response to EF
1 Present address: Department of Pathology, University of Saskatchewan, Saskatoon, Canada.IMMUNITY TO EF DURING TUMOUR INDUCTION
using the MMI test in hamsters bearing
transplanted SV40-induced tumours, and
Pasternak et al. (1976) demonstrated
sensitivity to EF in a variety of spontane-
ous or induced tumours of mice. In the
present paper, we report on the develop-
ment of a delayed hypersensitivity res-
ponse to EF in hamsters receiving varying
numbersofSV40-transformedtumourcells,
and in rats during the course of hepato-
carcinogenesis. In addition, the effects of
autologous serum upon EF-mediated
migration inhibition has been investigated
in some of the rats during hepatocarcino-
genesis.
MATERIALS AND METHODS
Animals.-Rats of the Wistar strain, 6-12
weeks old at the beginning ofthe experiment,
were obtained from a closed breeding colony
from the University of Sheffield Animal
House, and wereusedfortheinductionofliver
tumours. These animals were fed ad libitum
on Diet 86 (James Burnatt and Sons Ltd.,
Cleckheaton) and water, except were other-
wise stated. Hamsters were obtained from a
closedrandomlybred colonyattheUniversity
of Sheffield Animal House.
Carcinogenic diet.-A group of 46 Wistar
rats were fed ad libitum on Diet 86 containing
0.06% 4-dimethylamino-3'-methylazoben-
zene (3'-Me-DAB, Koch-Light Laboratories
Ltd., Colnbrook) in corn oil for a period of
12 weeks, after which they were returned to
the standard Diet 86. A control group of 10
animals was fed in parallel on Diet 86 con-
taining corn oil only. Three animals were
killed per week by cardiac puncture under
ether anaesthesia, from the 2nd week of
the start of the carcinogenic diet except on
Weeks 5 and 8 when 7 and 6 animals were
killed respectively. Two animals from the
control group were killed at the 4th week and
the remaining 8 animals at the 14th week.
Spleens and livers were removed aseptically
and placed into ice-cold Medium 199 (Well-
come Reagents Ltd., Beckenham) or alcoholic
formalin, respectively.
SV40-tumour transplantation.-A trans-
plantable SV40-induced tumour of hamsters
was used; this tumour was originally induced
by the inoculation of SV40 virus into a
newborn hamster, and has been maintained
for the past 5 years in this laboratory by s.c.
passage into weanling hamsters at 2-3-week
intervals. Tumours were excised aseptically
freed of necrotic tissue, chopped finely with
scalpel blades and further disrupted by
extrusion through a 1 ml syringe without a
needle. Debris was removed from the tumour-
cell suspension by filtration through muslin
cloth, and the tumour cells were washed x 3
with Medium 199 by centrifugation at 800 g.
Cell viabilities were estimated by trypan-blue
exclusion and the cells were adjusted to a
concentration of 102, 104 and 106 viable cells/
ml. Three groups of 15 hamsters were each
inoculated s.c. into the left flank with either
10, 103 or 105 tumour cells in a volume of
0 1 ml Medium 199 and 3 hamsters from each
group killed 4, 7, 10, 14 and 21 days later.
Tumour diameters of animals killed at these
times were measured with calipers and the
mean calculated.
Encephalitogenic factor.-EF was prepared
from human brain as previously described
(Flavell and Potter, 1978). Human EF made
by this method has been shown to cross-react
immunologically with hamster or rat EF as
determined by skin testing in guinea-pigs
immunized previously with human EF in
Freund's complete adjuvant.
Macrophage migration inhibition (MMI) test
Spleen-cell preparation.-Hamster or rat
spleens were removed aseptically and washed
briefly in ice-cold Medium 199. Hamster
spleens within each group were pooled, whilst
rat spleens were processed individually. The
spleens were briefly homogenized in Medium
199 and the fragments filtered through a
double layer of sterile muslin. Erythrocytes
were removed by flash lysis with distilled
water for 20 sec followed by the addition of
an equal amount of0-3Ml NaCl solution. The
cell suspension was washed x3 in Medium 199
containing 10% heat-inactivated foetal calf
serum, and the concentration ofcells adjusted
to 2-0x 106 viable cells/ml.
Peritoneal-exudate cell preparation.- Peri-
toneal-exudate cells (PEC) were induced in
Hartley guinea-pigs (200-400 g) by i.p. stimu-
lation with 10 ml of sterile liquid paraffin
(Hills Pharmaceuticals Ltd., Burnley). The
PEC were collected and processed as de-
scribed previously (Rees and Potter, 1973).
MMI test.-The ability of spleen cells to
produce macrophage migration inhibition
factor (MIF) when incubated with EF was
assessed with the direct MMI test. Full details
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of this test system have been given elsewhere
(Flavell and Potter, 1978). Briefly, spleen
cells and PEC were mixed in a ratio 1:5 and
packed into capillary tubes (10 1ul). Cut
capillary tubes were incubated in Medium 199
in the absence or presence of 100 Hug of EF
for 24 h at 37°C. Duplicate control wells
each containing 3 capillary tubes were set up
for each treatment. Areas of macrophage
migration were estimated at 24 h and the
percentage of migration inhibition with EF
calculated. The significance of observed
migration inhibition was assessed with the
Student's t test. A value of P<0 01 was
considered as indicative of significant migra-
tion inhibition.
Serum inhibition of EF-mediated migration
inhibition. Blood specimens collected from
rats by cardiac puncture were allowed to clot
at room temperature for 1 h and then centri-
fuged at 1500 g for 10 min. The serum was
harvested and heat-inactivated at 56°C for
30 min. The effects of autologous serum
upon EF-mediated migration inhibition were
investigated by including serum in duplicate
sets of wells at a concentration of 10% with
and without EF.
Histological examination of rat livers.-
Rat livers were fixed in alcoholic formalin,
and 6-8 representative portions were taken
for processing into paraffin wax. Sections were
cut and stained with haematoxylin and eosin
and also for reticulin. Sections were examined
by light microscopy without knowledge of
the results of the MMI test, and pathological
features wNere recorded using a simple scoring
system. After a period of weeks, the sections
were reassessed without reference to the first
results. Finally, sections from animals were
divided into 2 groups: from animals showing
significant migration with EF and from those
which did not. These 2 groups ofsections were
then presented unlabelled to a second patho-
logist to examine factors that might be
specific to eithergroup. Following the first and
second assessments, the rats were assigned
to 4 groups: Group 0, very little or no change;
Group 1, proliferative changes including
cholangiofibrosis; Group 2, dysplasia of
portal-tract epithelial cells; Group 3, cholan-
giocarcinoma.
RESULTS
Sensitivity to EF in SV40-tumour-bearing
hamsters
The results obtained for the direct
spleen-cell MMI test in hamsters bearing
SV40-induced tumours grown from 3
original tumour-cell inocula are shown in
Table I. Significant migration inhibition
with EF was not seen in any ofthe animals
until Day 21 after inoculation of tumour
TABLE I.-Mean Tumour Diameters (cm)
in Hamsters Receiving 10, 103 and 105
SV40-tamour Cells
Tumour
cell
inoculum 4
101 0
103 0
105 0-6
Days after inoculation
A
7 10 14 21
0 0 0 0-2
0 03 04 1-8
0 9 1-7 1-8 2-5
cells, when animals receiving 10 or 103
tumour cells showed migration inhibition
with EF at a significance level ofP<0 05.
Animals receiving 105 tumour cells showed
migration inhibition with EF at a signifi-
cance level of P<0 001 on Day 21. The
mean diameters of tumours borne by
hamsters tested with the MMI test on
Days 4, 6, 10, 14, and 21 are shown in
Table I. There was no correlation between
tumour size and the appearance of a
response to EF. Thus, 21 days after
inoculation of 10 tumour cells, animals
had a mean tumour diameter of 0-2 cm,
whilst animals that had received 103
tumour cells 21 days before had a mean
tumour diameter of 1P8 cm, yet both
groups showed a spleen-cell response to EF
with macrophage migration at a signifi-
cance level ofP<0 05. Conversely, animals
that had received 105 tumour cells 14 days
before had a mean tumour diameter of
1-8 cm but showed no response to EF at
this time.
Sensitivity to EF related to hepatic lesions in
rats
The results obtained for sensitivity to
EF as measured with the direct spleen-cell
MMI test in 46 rats with 3'-Me-DAB-
induced hepatic lesions and for 10 control
rats are shown in Table III and Fig. 2. Of
10 rats graded as minimum change
(Group 0), 2 (20%) showed significant
migration inhibition with EF. Of 16 rats
with hepatic lesions classified as proli-
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FIG. 1A.-Hepatic lesions n rats after 3'-Me-DAB administration. Early periporta cholangiofibrosis
with no dysplasia. x 80.
FIG. 1B.-Hepatic lesions in rats after 3'-Me-DAB administration. Marked cholangiofibrosis with
dysplasia of ductular epithelium. x 40.
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FIG. 1C.-Hepatic lesions in rats after 3'-Me-DAB administration. Small Focus of
cholangiocarcinoma. x 40.
ferative changes including cholangiofi-
brosis (Group 1), 2 (12%) showed signi-
ficant migration inhibition with EF,
whilst of 15 animals classified as dysplasia
of portal-tract epithelial cells (Group 2) 7
(46%) showed significant migration inhi-
bition with EF. All 5 animals classified as
cholangiocarcinoma (Group 3) showed a
response to EF. None of the 10 control
animals showed any response to EF.
Effects ofAutologous serum on EF-mediated
migration inhibition
The results obtained for the effects of
autologous serum on EF-mediated migra-
tion inhibition in 41 rats with 3'-Me-DAB-
induced hepatic lesions and in 10 control
rats are shown in Table IV. Serum from 6
animals in Group 0 had no effect on
migration inhibition with EF. EF-medi-
ated migrationinhibition wasabrogatedby
autologous serum in the one animal show-
ing significant migration inhibition with
EF from 15 animals in Group 1, whilst
serum from all 7 sensitized animals from
the group of 15 animals in Group 2
abrogated migration inhibition with EF.
HEPATIC LESION
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FIG. 2.-Percentage of significant 0 and
non-significant 0 MMI with EF by spleen
cells from rats with 3'-Me-DAB-induced
hepatic lesions.
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TABLE III.-MMI by Spleen Cells fromi
Rats with 3'-Me-DAB-induced Hepatic
Lesions in the Presence of EF
Hepatic
lesion
0
1
2
.3
Controls
No. tested
10
16
15
1()
No. (%) with
significant MMI
(P< 001)
2 (20%)
2 (12%)
7 (46%)
5 (100%)
0
EF-mediated migration inhibition was
abolished by autologous serum in 4/5
sensitized animals in Group 3. Autologous
serum had no effect on the macrophage
migrations in the 10 control animals.
DISCUSSION
A cell-mediated immune response to EF
in hamsters with experimental tumours
has been demonstrated previously. Thus,
Shelton et al. (1975) have shown that
hamsters bearing SV40-induced tumours
show a response to EF with the MMI test
10 days after tumour implantation, and
Pasternak et al. (1.976) have shown a
response to EF in mice bearing tumours of
different aetiology. However, no studv
has been made in an animal model system
to investigate the point during tumour
progression at which sensitivity to EF
becomes apparent. In humans, the studies
of Singer et al. (1975) and Porzsolt et al.
(1975) have shown that a high proportion
of women with dysplastic lesions of the
cervix show a lymphocyte response to EF
withthe MMI and MEMtests, respectively.
These results suggest that a lymphocyte
response to EF occurs early in tumour
development.
The results of the present study have
shown that hamsters bearing transplanted
SV40 tumours show a spleen-cell response
to EF 21 days after implantation of
tumour cells. Thus, spleen cells from
animals receiving tumour-cell inoculum of
105 cells gave MMI with EF at a signifi-
cance level of P<0 00] 21 days after
implantation. Many workers accept P<
0 05 as indicative of significant migration
inhibition, but from our stringent statisti-
cal analysis spleen cells from animals
receiving 10 or 103 SV40-tumour cells,
which gave MMI with EF at a significance
level of P<005 21 days after implanta-
tion, cannot be considered as significant.
It might therefore be concluded that the
immune response to EF in animals
bearing SV40 tumours takes up to 21 days
to develop, and that its development to a
highly significant level is dependent upon
the size of tumour cell inoculum.
The observations made in rats with 3'-
Me-DAB-induced hepatic lesions suggest
that a cell-mediated immune response to
EF occurs before the appearance of a
carcinoma. The gross and microscopic
appearances of the rat livers were similar
to those described by other workers using
3'-Me-DAB and related carcinogens (Orr,
1940; Richardson and Borsos-Nachtnebel,
1951; Price, Miller and Miller, 1959;
(Goldfarb, 1973) and, in particular the
finding of cholangiocarcinoma and not
hepatocellular carcinoma by Reddy,
Buschmann and Chomet (1977). These
workers have applied a variety of inter-
pretations to the spectrum of changes
seen, and the difficulties of classification
are reflected in this study. However, all
authors agree that there is some form of
identifiable pre-neoplastic lesion. Gold-
TABLE IV. IIMI by Spleen Cells from Rats with 3'-Me-DAB-induced Hepatic Lesions
in the Presence of EF, with and without Autologous Serum.
No. (%o) with significant MMI (P<001)
No serum With serum
1 (17%) 1 (17%)
1 (7%) 0
7 )46%) 0
5 (100%) 1 (20%)
0
Hepatic
lesion
0
1
2
Controls
No.
testedi
6
15
15
5
8
No. with
blocking
activity
0
1
7
4
0
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farb (1973) investigated some histochemi-
cal features of lesions which were con-
sidered neoplastic, whilst Boyd, Louis and
Martin (1974) investigated biochemical
attributes during tumour induction.
Whilst the observations of the present
study suggest that a cell-mediated immune
response to EF occurs in association with
dysplastic lesions, it is possible that due
to inadequate sampling small foci of
mnalignant change were not discovered, but
this seems unlikely in every case. The find-
ings that rats with dysplastic hepatic
lesions show a response to EF are in
agreement with the observations of other
workers, in which lymphocyte sensitivity
to EF was found in women with dysplastic
cervical lesions (Singer et al., 1975;
Porzsolt et al., 1975). It is not possible
to say whether the spleen-cell response to
EF seen in the rats with dysplastic
hepatic lesions was due to the appearance
of neoantigen(s) on the dysplastic epithe-
lial cell surface immunologically cross-
reactive with EF (Caspary and Field,
1971) or to tissue damage by the carcino-
gen or neoplasm resulting in the release or
normally sequestered tissue components
which subsequently immunize the host
(Mitchell, 1973). Indeed, the appearance
of a delayed hypersensitivity response to
EF in some animals or humans bearing
potentially malignant dysplastic lesions
might indicate the malignant potential of
these lesions.
Serum abrogation of EF-mediated MMI
was seen early in hepatocarcinogenesis in
the one sensitized animal with prolifera-
tive changes and cholangiofibrosis and in
all 7 sensitized animals with dysplastic
hepatic lesions. Of the 5 sensitized rats
with cholangiocarcinomas, 4 showed serum
abrogation of EF-mediated MMI. Flavell
and Potter (1978) have demonstrated the
abrogation of EF-mediated MMI in
patients with cancer, and have shown that
this abrogatory effect is independent ofthe
extent of disease, and operates in the
homologous situation between individuals
with different tumour types. The observa-
tions made in the present study suggest
that the serum-blocking effect observed is
different from those seen by workers using
tumour-specific antigens or whole viable
tumour cells in microcytotoxicity assays,
where serum blocking activity correlates
well with the extent of the disease
(Currie, 1973; Bray and Holt, 1975). The
nature and significance of the serum
effectseeninthepresentstudyisunknown;
it is possibly due to the release or produc-
tion of immunoregulatory substances dur-
ing tissue damage, with the role of modu-
lating the immune response and thus pre-
venting the occurrence of an autoimmune
reaction to released normal tissue compo-
nents. In support ofthis are the findings of
Bernard and Lamoureux (1975) who have
demonstrated that the aX2 macroglobulin
component ofserum suppiesses the ability
of EF to induce allergic encephalomyelitis
in guinea-pigs.
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